Clinical Trials


  • A closeup of Boston Scientific's Watchman FLX device is shown against a white background.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific’s Watchman could be new option for patients post ablation: study

    The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent cardiac ablation for AFib.

    By Nov. 18, 2024
  • A Black man with dreads rests in-bed
    Image attribution tooltip

    Photo by MART PRODUCTION from Pexels

    Image attribution tooltip

    Livanova hits sleep apnea trial goals, plans FDA filing

    Leerink analysts said the results were largely in line with outcomes in a trial of Inspire Medical’s rival device but cautioned that Livanova may have a hard time breaking into the sleep apnea market.

    By Nov. 13, 2024
  • Johnson & Johnson's new logo is seen on an office lobby wall.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J’s Ottava surgical robot to begin clinical trial after FDA nod

    With FDA approval of an investigational device exemption, J&J’s soft tissue robot moves a step closer to challenging Intuitive Surgical’s da Vinci system.

    By Nov. 12, 2024
  • Boston Scientific's Farapulse pulsed field ablation device.
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip

    Boston Scientific resumes PFA trial in new patient group after pausing enrollment

    Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to anti-arrhythmic drugs in patients with persistent AFib, a spokesperson said.

    By Nov. 12, 2024
  • A view of the Edwards Lifesciences headquarters building with three people walking in front.
    Image attribution tooltip
    Courtesy of Edwards Lifesciences
    Image attribution tooltip

    Edwards, Medtronic and Inari share trial data at TCT conference

    The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the companies and their device markets.

    By Oct. 31, 2024
  • Boston Scientific's Acurate neo2 TAVR device is shown close up against a white background.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific’s Acurate Neo2 inferior to rival TAVR valves in study

    Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

    By Oct. 31, 2024
  • Edwards data show benefit of early TAVR over ‘watchful waiting’

    Study author Philippe Genereux said the trial data “shatter 60 years of ingrained belief on the treatment for severe aortic stenosis.”

    By Oct. 29, 2024
  • An illustration of a heart bump inserted into a heart against a blue background.
    Image attribution tooltip
    Courtesy of Abiomed
    Image attribution tooltip

    J&J to seek FDA approval after small-bore Impella heart pump hits trial goal

    The company has predicted the narrower Impella ECP will be easier to insert and implant, as well as enable the use of small bore access and closure techniques.

    By Oct. 29, 2024
  • An exterior of a building with a sign that says "Welcome to #MTC24" in front of a downtown skyline.
    Image attribution tooltip
    Elise Reuter/MedTech Dive
    Image attribution tooltip
    The Medtech Conference

    That’s a wrap: 5 takeaways from The Medtech Conference

    The conference — Advamed’s largest — featured an appearance by the device center’s new acting director and sessions on AI, clinical trial diversity and the FDA’s contentious LDT rule.

    By Oct. 22, 2024
  • A picture of a medical catheter against a white background.
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott enrolls pivotal PFA study 4 months ahead of schedule

    The company reported the enrollment milestone alongside news that it received clearance to sell its Advisor HD Grid X Mapping Catheter and started a trial of its Tactiflex Duo Ablation Catheter.

    By Oct. 11, 2024
  • An image of the Procept Biorobotics system against a white background.
    Image attribution tooltip
    Courtesy of Procept Biorobotics
    Image attribution tooltip

    Procept secures FDA approval to study surgical robot in prostate cancer

    The trial will compare the therapy to radical prostatectomy and could unlock a market that analysts value at $500 million.

    By Oct. 9, 2024
  • A nighttime shot of Chicago's downtown and river.
    Image attribution tooltip
    halbergman via Getty Images
    Image attribution tooltip

    Top medtech conferences in 2025

    The lineup includes industrywide conferences and events covering the latest medtech trends in diabetes, orthopedics, cardiac care and surgical robotics.

    By Oct. 1, 2024
  • A picture of Synchron's brain-computer interface device against a white background.
    Image attribution tooltip
    Courtesy of Synchron
    Image attribution tooltip

    Synchron’s brain-computer interface tech meets safety goal

    The six-patient trial also indicated the device worked, according to Synchron, with the conversion of brain signals to motor outputs allowing people to perform digital tasks.

    By Oct. 1, 2024
  • Senior Research Associate Tanya Quint loads one of the instruments used to run Exact Sciences' Cologuard test at the company's headquarters in Madison, Wis. (Photo: Business Wire)
    Image attribution tooltip
    Courtesy of Business Wire/Exact Sciences
    Image attribution tooltip

    Exact Sciences says data support its colon cancer blood test

    Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

    By Sept. 16, 2024
  • Food And Drug Administration Headquarters In Maryland
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA seeks feedback on health equity for medical devices

    The agency plans to develop a framework for when devices should be evaluated in diverse populations to support marketing authorization.

    By Aug. 6, 2024
  • The headquarters of the FDA, which has recently issued a recall for Teleflex air filters used in hospital respirators.
    Image attribution tooltip
    Sarah Silbiger/Getty Images via Getty Images
    Image attribution tooltip

    FDA finalizes guidance on studying opioid use disorder treatments

    The Center for Devices and Radiological Health is aiming to help companies manage challenges such as inaccurate participant reports of drug use.

    By July 12, 2024
  • Food And Drug Administration Headquarters In Maryland
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA shares draft guidance on clinical trial diversity action plans

    The agency said which trials need diversity action plans and presented the timeline for implementing the requirement.

    By June 28, 2024
  • A person sits in front of a plate of food, holding a smartphone. They're wearing a patch on their left arm.
    Image attribution tooltip
    Courtesy of Insulet Corp.
    Image attribution tooltip

    Insulet seeks label expansion of Omnipod 5 for Type 2 diabetes

    At the American Diabetes Association meeting, Insulet shared study results showing improvements in blood glucose and quality of life.

    By June 24, 2024
  • A female doctor and senior patient discuss medical records.
    Image attribution tooltip
    SDI Productions via Getty Images
    Image attribution tooltip

    Women underrepresented in trials of high-risk medical implants: study

    A median of 33% of study subjects were women, and the figure was significantly lower in cardiovascular trials.

    By June 12, 2024
  • Sapien valve performs equally well for small and large aortic annuli, Edwards finds

    The analysis adds to a debate about the effectiveness of Edwards versus Medtronic TAVR devices in patients with small aortic annuli, a fibrous ring around the heart’s valve.

    By June 6, 2024
  • Prostate cancer cells, 3D illustration. Prostate cancer awareness image
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Saliva test identifies men at high risk of prostate cancer

    Data presented at the American Society of Clinical Oncology meeting suggest the test can support prostate cancer diagnosis in people who are missed by other screening methods.

    By June 5, 2024
  • Photo of Michael F. Mahoney, CEO of Boston Scientific.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific’s cardiac rhythm system hits pivotal trial goals

    Boston Scientific, which presented the results at the Heart Rhythm Society meeting, expects to receive FDA approval for the system in 2025.

    By May 21, 2024
  • A photo of Johnson & Johnson's pulsed field ablation system for atrial fibrillation.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J posts latest Varipulse data while awaiting FDA review

    Johnson & Johnson is chasing Medtronic and Boston Scientific in the U.S. for a share of the rapidly growing pulsed field ablation market.

    By May 20, 2024
  • The latest Apple Watch will include entirely fiber-based packaging for the first time
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    FDA qualifies Apple Watch AFib feature for use in clinical trials

    Officials will accept atrial fibrillation data collected by the wearable as a secondary endpoint in studies of cardiac ablation devices. 

    By May 6, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly obesity drug shows benefit in sleep disorder study, pointing to new use

    Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.

    By Jonathan Gardner • April 17, 2024